Results 101 to 110 of about 1,463,292 (235)

May Fever Trigger Ventricular Fibrillation? [PDF]

, 2005
The clinical precipitants of ventricular fibrillation (VF) remain poorly understood. Clinical factors such as hypoxemia, acidosis or electrolyte imbalance, drug-related toxicity, autonomic nervous system disorders as well as viral myocarditis have been ...
Pasquié, Jean Luc
core   +1 more source

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J.H. Schatorjé, Esther P.A.H. Hoppenreijs, Joost F. Swart, Marc H.A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert   +14 more
wiley   +1 more source

Scarlet-Fever

Science, 1888
n ...
openaire   +2 more sources

Yellow fever disease : density equalizing mapping and gender analysis of international research output [PDF]

, 2013
Background: A number of scientific papers on yellow fever have been published but no broad scientometric analysis on the published research of yellow fever has been reported. The aim of the article based study was to provide an in-depth evaluation of the
Bundschuh, Matthias, Gerber, Alexander, Groneberg, Jan David Alexander, Klingelhoefer, Doris   +3 more
core  

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

A novel treatment of biogas digestate waste for biochar production and its adsorption of methylene blue and malachite green in a binary system

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study presents a novel treatment of biogas digestate to produce biochar at processing temperatures of 500–700 °C. The resulting biochar was applied for the simultaneous removal of methylene blue (MB) and malachite green (MG) in a binary system.
Van Hau Duong, Pham Xuan Phuong, Phan Thi Duy Thuan, Altyn Taisheva, Dinh Van Dung, Le Dinh Phung, Nguyen Thi Hong Bich, Nguyen Duy Luu, Dinh Quang Khieu, Filip Mercl, Hynek Roubík   +10 more
wiley   +1 more source

Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Aim PREDICT‐5FU aimed to document 5‐fluorouracil (5FU) exposure in a cancer population and to evaluate the feasibility of 5FU and capecitabine therapeutic drug monitoring (TDM) in patients receiving standard doses and schedules. Methods Multicentre, prospective, observational single‐arm study.
Sarah Glewis, Michael Michael, Howard Gurney, Ian Olver, Nicholas Zdenkowski, Stephen Ackland, Craig Kukard, Madawa Jayawardana, S. Sandun M. Silva, Marliese Alexander, Jeanne Tie, Peter Galettis, Jennifer H. Martin   +12 more
wiley   +1 more source

Paracetamol and its metabolites in children and adults with spinal muscular atrophy – a population pharmacokinetic model

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of the study was to investigate whether differences in paracetamol pharmacokinetics (PK) between spinal muscular atrophy (SMA) patients and healthy controls (HC) could be attributed to specific clinical covariates. Methods Nonlinear mixed‐effects modelling (NONMEM 7.4) was used to develop a population PK model, explore covariates ...
Qiaolin Zhao, Marie Mostue Naume, Brenda C. M. de Winter, Thomas Krag, Sissel Sundell Haslund‐Krog, Karoline Lolk Revsbech, John Vissing, Helle Holst, Morten Hylander Møller, Tessa Munkeboe Hornsyld, Morten Dunø, Christina Engel Hoei‐Hansen, Alfred Peter Born, Per Bo Jensen, Mette Cathrine Ørngreen   +14 more
wiley   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding

British Journal of Clinical Pharmacology, EarlyView.
Aims We aimed to describe suspected adverse drug reactions (ADRs) in infants resulting from medications transmitted through mothers' milk, as reported to the European ADR database, EudraVigilance. The research sought to understand the frequency, seriousness and nature of these ADRs to assess potential risks associated with maternal medication use ...
Ida M. Heerfordt, Ditte Resendal Gotfredsen, Henrik Horwitz, Anette Kirstine Stark, Jon Trærup Andersen, Christina Gade, Ulrik Lausten‐Thomsen, Rasmus Huan Olsen   +7 more
wiley   +1 more source